Last reviewed · How we verify
NCT04143815
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
Phase 2 trial testing MBA-P01 (Botulinum toxin A) in Glabellar Frown Lines in 200 participants. Completed in 1 September 2020.
1 September 2020
Quick facts
| Lead sponsor | Medy-Tox |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 20 May 2019 |
| Primary completion | 1 September 2020 |
| Estimated completion | 1 September 2020 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- MBA-P01 (Botulinum toxin A) — full drug profile →
- Placebo
Conditions studied
- Glabellar Frown Lines — all drugs for Glabellar Frown Lines →
Sponsor
Medy-Tox — full company profile →
Who can join
18 and older, any sex, with Glabellar Frown Lines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, Gemperli R, et al · · 2021 · cited 21× · PMID 34224576 · DOI 10.1002/14651858.cd011301.pub2
Verify or expand the search:
- PubMed search for NCT04143815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MBA-P01 (Botulinum toxin A)
Trials testing the same drug.
- NCT05217355 — A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines · Phase 2 · completed
Other Medy-Tox trials
Trials by the same sponsor.
- NCT05195112 — Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 3 · completed
- NCT04157686 — MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) · Phase 3 · completed
- NCT04281745 — Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® · Phase 4 · unknown
- NCT04144049 — A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 2 · completed
- NCT04143854 — Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04143815 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medy-Tox
- Last refreshed: 19 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04143815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing